Welcome to our dedicated page for Viemed Healthcare SEC filings (Ticker: VMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Viemed Healthcare, Inc. filings document the public-company reporting of a British Columbia issuer with Nasdaq-listed common shares and a U.S. home-based healthcare business. Recent Form 8-K reports furnish quarterly and annual financial results, financial supplements, guidance updates, investor presentation materials, and Regulation FD disclosures tied to Viemed's home medical equipment and chronic disease management operations.
The filing record also covers capital and governance matters, including a definitive proxy statement with annual meeting, governance, and executive compensation disclosures; credit agreement amendments involving Viemed subsidiaries and lenders; and common-share repurchase authorizations and completed repurchase activity. These filings describe the company's capital structure, material agreements, board actions, and formal disclosure controls around furnished operating updates.
Viemed Healthcare, Inc. reported the results of its Annual General and Special Meeting. Shareholders approved a second amendment to the 2024 Long Term Incentive Plan, increasing the maximum number of common shares reserved for issuance under current and prior equity plans to 7,696,717, including up to 1,000,000 incentive stock options. All seven director nominees were elected, each receiving at least 79.76% support, with broker non-votes of 5,139,303 on the election item. Shareholders also approved the appointment of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026. The equity plan amendment and executive compensation received strong backing, with 88.85% and 93.21% of votes cast in favor, respectively, on the compensation-related resolutions.
Viemed Healthcare highlights strong growth and guidance in its June 2026 investor presentation. Net revenue reached $270 million in 2025, up 28% year over year, with Adjusted EBITDA of $61 million and free cash flow of $28 million, all with no net debt. The company reports a 26% compounded annual revenue growth rate since listing, serves over 183,000 patients across all 50 states, and has diversified beyond ventilation into sleep, oxygen, airway clearance, women’s health and staffing. For 2026, Viemed guides to net revenue of $312–$320 million and Adjusted EBITDA of $65–$69 million, while maintaining net capex at 9–10.5% of revenue and trailing twelve-month free cash flow of about $36 million. Management is also executing a new share repurchase program of up to 5% of shares outstanding, supported by cash generation and $46 million of credit facility availability.
Viemed Healthcare, Inc. reported strong top-line growth for the quarter ended March 31, 2026. Revenue rose to $75.4 million from $59.1 million, driven by broader rental activity and a sharp increase in equipment and supply sales.
Ventilator rentals generated $35.4 million and other home medical equipment rentals $16.2 million, while equipment and supply sales more than doubled to $17.5 million, aided by women’s health products and the Lehan Drugs acquisition. Gross margin was 56.8%, slightly above last year.
Net income attributable to Viemed was $2.6 million, essentially flat year over year, with diluted EPS of $0.06. Operating cash flow improved to $8.1 million, supporting $6.7 million of capital spending and $3.2 million of debt repayment. Cash ended at $9.8 million and total debt at $9.6 million, with shareholders’ equity of $145.8 million.
Viemed Healthcare reported strong first quarter 2026 growth while narrowing and raising its full-year outlook. Net revenue for the quarter ended March 31, 2026 was $75.4 million, up 28% from the prior-year quarter. Net income attributable to Viemed was $2.6 million, or $0.06 per diluted share, and Adjusted EBITDA rose 12% to $14.3 million, despite a non-recurring gain in the prior year.
The company generated $8.1 million of operating cash flow and $2.6 million of free cash flow in the quarter, repurchased 150,000 shares for $1.4 million, and reduced term debt by $3.2 million. Management now expects 2026 net revenue of $312–$320 million, Adjusted EBITDA of $65–$69 million, and lower net capital intensity of 9%–10.5% of net revenue.
Viemed Healthcare, Inc. is calling a 2026 annual general and special meeting to elect seven directors, ratify Ernst & Young LLP as auditor, amend its 2024 Long Term Incentive Plan, and hold a non-binding say‑on‑pay vote.
The equity plan amendment would lift the combined share reserve under current and prior equity plans to 7,696,717 common shares, or 20% of the 38,483,586 shares outstanding as of April 8, 2026. Directors and executive officers together beneficially own 7,912,538 shares, or 20.6% of outstanding shares, while BlackRock, Inc. and Forager Fund, L.P. hold 6.6% and 7.1%, respectively.
Viemed Healthcare, Inc. President Michael Moore reported open-market sales of Common Shares indirectly held through Moore Faster LLC. The LLC sold 31,570 shares on March 18 at a weighted-average price of $9.42, 40,232 shares on March 19 at $9.21, and 65,000 shares on March 20 at $8.77 per share. Footnotes state each reported price is a weighted average for multiple trades in ranges of $9.26–$9.61, $9.04–$9.38, and $8.63–$9.18, respectively. Following these transactions, Moore Faster LLC held 1,585,812 Common Shares indirectly, and Michael Moore also held 189,090 Common Shares directly.
Morgan Stanley Smith Barney LLC submitted a notice under Rule 144 regarding the proposed sale of 65,000 shares of Common stock of the issuer. The filing identifies MOORE FASTER LLC as a selling holder with recent sales reported on 03/19/2026 and 03/18/2026.
The filing lists two recent transactions by MOORE FASTER LLC: 40,232 shares sold on 03/19/2026 and 31,570 shares sold on 03/18/2026, with cash amounts shown alongside each sale.
VMD reported a Form 144 disclosing a sale of 31,570 common shares by MOORE FASTER LLC on 03/18/2026. The reported proceeds were $297,345.20. The transaction lists Morgan Stanley Smith Barney LLC as the broker/financial intermediary.